U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047547) titled 'A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure' on June 24.
Brief Summary: Chronic Kidney Disease often requires dialysis and other treatments to sustain life, and patients frequently suffer from heart failure, which exacerbates the disease burden. Research has shown that the incidence of heart failure is high among patients on dialysis, and the prognosis is poor. In recent years, there has been significant progress in the treatment of heart failure. Vericiguat, a novel sGC stimulator, can improve cardiac function and exercise tolerance, reduce the risk of cardiovascular death and...